Discovery of potent c-MET inhibitors with new scaffold having different quinazoline, pyridine and tetrahydro-pyridothienopyrimidine headgroups

Article abstract of DOI:10.3390/molecules21050612

Cellular mesenchymal-epithelial transition factor (c-MET) is closely linked to human malignancies, which makes it an important target for treatment of cancer. In this study, a series of 3-methoxy-N-phenylbenzamide derivatives, N-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl) benzamide derivatives and N¹-(3-fluoro-4-methoxyphenyl)-N³-(4-fluorophenyl) malonamide derivatives were designed and synthesized, some of them were identified as c-MET inhibitors. Among these compounds with new scaffolds having different quinazoline, pyridine and tetrahydro-pyridothienopyrimidine head groups, compound 11c, 11i, 13b, 13h exhibited both potent inhibitory activities against c-MET and high anticancer activity against tested cancer cell lines in vitro. In addition, kinase selectivity assay further demonstrated that both 13b and 13h are potent and selective c-MET inhibitors. Molecular docking supported that they bound well to c-MET and VEGFR2, which demonstrates that they are potential c-MET RTK inhibitors for cancer therapy.

Full text of DOI:10.3390/molecules21050612

molecules
Article
Discovery of Potent c-MET Inhibitors with New
Scaffold Having Different Quinazoline, Pyridine and
Tetrahydro-Pyridothienopyrimidine Headgroups
Yingnan Jiang, Ke Zhang, Suyu Gao, Guihua Wang, Jian Huang, Jinhui Wang * and Lixia Chen *
School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China;
j1074736705@163.com (Y.J.); xjzk1984@163.com (K.Z.); gsy19900922@163.com (S.G.); redticky@126.com (G.W.);
13504051049@163.com (J.H.)
* Correspondence: profwjh@126.com (J.W.); syzyclx@163.com (L.C.); Tel./Fax: +86-24-23986479 (J.W. & L.C.)
Academic Editor: Derek J. McPhee
Received: 23 March 2016; Accepted: 5 May 2016; Published: 11 May 2016
Abstract: Cellular mesenchymal-epithelial transition factor (c-MET) is closely linked to human
malignancies, which makes it an important target for treatment of cancer. In this study, a
series of 3-methoxy-N-phenylbenzamide derivatives, N-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)
benzamide derivatives and N1-(3-fluoro-4-methoxyphenyl)-N3-(4-fluorophenyl) malonamide
derivatives were designed and synthesized, some of them were identified as c-MET inhibitors.
Among these compounds with new scaffolds having different quinazoline, pyridine and
tetrahydro-pyridothienopyrimidine head groups, compound 11c, 11i, 13b, 13h exhibited both potent
inhibitory activities against c-MET and high anticancer activity against tested cancer cell lines
in vitro. In addition, kinase selectivity assay further demonstrated that both 13b and 13h are potent
and selective c-MET inhibitors. Molecular docking supported that they bound well to c-MET and
VEGFR2, which demonstrates that they are potential c-MET RTK inhibitors for cancer therapy.
Keywords: quinazoline; pyridine; tetrahydro-pyridothienopyrimidine; MET inhibitor; cancer therapy
1. Introduction
Tyrosine kinase is an enzyme that transfers a phosphate group from ATP to a protein, and it
functions as an “on” or “off” switch in many cellular functions. They become potent oncogene that
has the potential to cause cancer, when they are often mutated or expressed at high levels [1]. Several
receptor tyrosine kinases (RTKs) inhibitors have been found to have effective anti-tumor activity and
some of them have been approved or are in clinical trials. Recent FDA approved drugs Sorafenib
(Nexavar) [2] is such example of multi-targeted agents (Figure 1).
H
H
N
N
O
N
O
O
HN
N
N
O
N
F
H
O
O
2
1, XL184
F
CF3
O
Cl
HN
O
H
BocN
N
N
N
N
H
N
H
O
S
N
3, Sorafenib
4
Figure 1. Representative c-MET inhibitor (1, XL184) and Multi-kinase inhibitor (2–4).
Molecules 2016, 21, 612; doi:10.3390/molecules21050612
www.mdpi.com/journal/molecules

Molecules 2016, 21, 612
2 of 16
Cellular mesenchymal-epithelial transition factor (c-MET), the hepatocyte growth factor receptor
(HGFR), belongs to a subfamily of RTK that are composed of an extracellular a chain and a
membrane-spanning b chain connected through a disulfide bond [
Factor/Scatter Factor (HGF/SF) to c-MET induces phosphorylation of tyrosine residues on c-MET and
activates its downstream signaling pathway [ ], which is associated with cell proliferation, migration,
invasion and survival and is essential for normal embryonic development and wound healing [ ].
3–5]. Binding of Hepatocyte Growth
6,7
8,9
However, it is reported that the c-MET/HGF axis is also involved in the development of various
human malignancies. Aberrant or mutated expression of c-MET/HGF axis has been observed in a
number of malignancies such as breast, gastric, bladder and lung cancers, which is closely linked
to tumorigenesis and metastasis [10–12]. Moreover, it is reported that dysregulation of c-MET also
correlated with a poor prognosis in clinical studies [13]. Therefore, c-MET shows high potential as a
therapeutic target for human cancer.
Well-known agents for targeting the c-MET/HGF axis include anti-HGF antibodies, anti-c-MET
antibodies, and c-MET tyrosine kinase inhibitors (TKIs). Among them, c-MET TKIs are the most
attractive means to target c-MET pathway, because they are thought to be effective against both
ligand-dependent and ligand-independent activation of c-MET [14]. In recent years, a number of c-MET
inhibitors have been reported or have entered clinical trials, and many of them are c-MET/VEGFR-2
(vascular endothelial growth factor receptor 2) dual inhibitors (see Figure 1) [15
–17]. For example,
Cabozantinib (XL184, BMS-907351) is a potent c-MET inhibitor with IC50 of 1.3 nM and also inhibits
VEGFR2, Ret, Kit, Flt-1/3/4, Tie2, and AXL in cell-free assays, respectively. Compounds
2
and
4
represent potential lead compounds with c-MET inhibitory effect in high throughput screening [18
,19].
There are two classes of c-MET inhibitors based on their chemical structures or binding modes, but
they both have some shortcomings [20 21]. Class I inhibitors bind in a U-shaped conformation to the
,
ATP-binding site at the entrance of a kinase pocket, wrap around Met1211 and bind to a hinge-block,
and thus specifically inhibiting MET kinases, such as Crizotinib. Class II inhibitors bind to a region of
MET that extends from the ATP binding site to Ile1145 near the C-C-spiral block, such as Cabozantinib.
Studies suggested that class II inhibitors maybe more effective than class I inhibitors, but they exhibited
off-target effects of other protein kinases, and clinical use of class II inhibitors have shown that these
agents cause serious toxic effects in many organs [22–25]. Therefore, potent c-MET inhibitors with
improved selectivity and minimal side effects should be developed.
In this study, we disclose our efforts towards the design and synthesis of new c-MET inhibitors. To
further understand the structure–activity relationship (SAR) of this novel series of compounds, different
quinazoline, pyridine and tetrahydro-pyridothienopyrimidine fragments were investigated. A series
of 3-methoxy-N-phenylbenzamide derivatives, N-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl) benzamide
derivatives and N1-(3-fluoro-4-methoxyphenyl)-N3-(4-fluorophenyl) malonamide derivatives were
synthesized, and their inhibitory activities against c-MET and three different cancer cell lines were
evaluated. We were interested to see if such modifications were possible within our new classes of
molecules compared to the parent compounds.
2. Results and Discussion
2.1. Chemistry
The chemistry described in Scheme 1 shows the synthetic route chosen to obtain quinazolines
(Compound
5), pyridines (Compound 6) and tetrahydro-pyridothienopyrimidines (Compound 7)
fragments. The reaction of 2-amino-4,5-dimethoxybenzoic acid with formamidine acetate afforded
intermediate 6,7-dimethoxyquinazolin-4-ol, which upon reaction with SOCl2 afforded compound 5.
The synthetic method of compound 7 is similar to the above process [26,27].

Molecules 2016, 21, 612
3 of 16
Scheme 1. The synthesis procedure of the three different headgroups. Reagents and conditions:
(i) Formamidine acetate, CH3OCH2CH2OH, 125 ˝C, 16 h; (ii) THF, SOCl2, reflux, 3 h; (iii) DMF,
SOCl2, 120 ˝C, 6 h; (iv) THF, EDCI, CH3NH2, rt., 3 h; (v) S, NCCH2CO2Et, EtOH, Et3N, rt, 16 h;
(vi) Formamidine acetate, DMF, 120 ˝C, 16 h; (vii) POCl3, DIPEA, toluene, 80 ˝C, 12 h.
The chemistry described in Scheme 2 shows compound libraries could be made simply by
using the reaction protocol with N-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-hydroxybenzamide
(Compound
8
) and different head groups. A cyclization reaction with nitrile and hydrazine was
was synthesized by a
carried to afford 3-(tert-butyl)-1-phenyl-1H-pyrazol-5-amine. Compound
conventional peptide synthesis method using ClCOCOCl at 0 C [28].
8
˝
Scheme 2. The synthesis procedure of Compound 9a–c. Reagents and conditions: (i) EtOH, reflux, 16 h;
(ii) THF, 3-hydroxybenzoic acid, ClCOCOCl, 0 ˝C, 3 h; (iii) 5, 6 or 7, DMF, K2CO3, 80 ˝C, 24 h.
Inspired by the structure of the lead compound
4, we have also designed a series of
N-phenylbenzamide derivatives. The synthetic route is shown in Scheme 3. Compounds 10
were synthesized by a conventional peptide synthesis method with aniline and benzoic acid using
ClCOCOCl at 0 ˝C. Then, a typical Williamson ether synthesis was carried on to afford compound
11a–i [29].

Molecules 2016, 21, 612
4 of 16
Scheme 3. The synthesis procedure of Compound 11a
–i. Reagents and conditions: (i) THF, ClCOCOCl,
0 ˝C, 3 h; (ii) 5, 6 or 7, DMF, K2CO3, 80 ˝C, 24 h.
We also combined different head groups to the side chain of lead compound 1, XL184. The
synthetic route is shown in Scheme 4. After multi-step protection and de-protection reaction, a series
ethyl hydrogen malonate derivative was obtained. Then, Compounds 12 were synthesized by a
conventional peptide synthesis method using isobutyl chloroformate and 4-Methylmorpholine. After
that, a typical Williamson ether synthesis was carried on to afford compound 13a–i [30].
Scheme 4. The synthesis procedure of Compound 13a
5 h, or 1,2-dibromoethane or 1,3-dibromopropane, Bu4NBr, K2CO3, DMF, rt., 12 h; (ii) KOH, EtOH,
–i
. Reagents and conditions: (i) EtONa, CH3I, 0 ˝C,
0 ˝C, 5 h; (iii) 4-amino-2-fluorophenol, IBCF, NMM, THF,
´
15 ˝C, 5 h; (iv) KOH, EtOH, 0 ˝C, 5 h;
(v) 4-fluoroaniline, IBCF, NMM, THF, ´15 ˝C, 3 h; (vi) 5, 6 or 7, DMF, K2CO3, 80 ˝C, 24 h.
2.2. Biology
2.2.1. Kinase Inhibitory Assay
All the synthesized compounds were assayed with the enzymatic activity against c-MET. The
results were summarized in Tables 1–3. Also included was the representative c-MET inhibitor (XL184).
Among these compounds, compound 11c, 11i, 13b, 13h showed potent inhibitory activity against
c-MET, with IC50 of 0.08
µM (11c), 0.05 µM (11i), 0.02 µM (13b), 0.05 µM (13h), which is compared to
XL184 (IC50 = 0.03 µM against c-MET).

Molecules 2016, 21, 612
5 of 16
Table 1. Enzymatic and cellular results for compound 9a–c.
Enzymatic Inhibition (IC50, µM) a,b
Proliferative Inhibition (IC50, µM) b
Compound
9a
A
c-MET
HeLa
Hep-G2
MCF-7
8.4 ˘ 0.6
>10
28.7 ˘ 1.1
38.5 ˘ 1.3
46.1 ˘ 0.8
9b
>100
>100
>100
>100
59.7 ˘ 1.3
66.7 ˘ 1.5
9c
>10
a
Prior to the initiation of the kinase reaction with ATP (10 µM), compounds and enzyme were incubated
b
for 30 min. IC50 values obtained with viability assays. Each value is representative of three independent determinations.
Table 2. Enzymatic and cellular results for compound 11a–c.
Enzymatic Inhibition (IC50, µM) a,b
Proliferative Inhibition (IC50, µM) b
Compound
11a
A
R
c-MET
HeLa
Hep-G2
MCF-7
3,4-diOMe
0.52 ˘ 0.05
14.1 ˘ 0.16
>100
3.4 ˘ 0.21
11b
11c
4-Cl
4-F
0.12 ˘ 0.03
0.08 ˘ 0.04
1.8 ˘ 0.06
0.9 ˘ 0.12
9.2 ˘ 0.17
10.1 ˘ 0.20
7.8 ˘ 0.14
5.2 ˘ 0.36
11d
3,4-diOMe
>10
>100
>100
71.2 ˘ 0.34
11e
11f
4-Cl
4-F
7.4 ˘ 0.07
5.3 ˘ 0.05
26.4 ˘ 0.20
27.8 ˘ 0.34
>100
>100
34.5 ˘ 0.36
42.1 ˘ 0.27
11g
3,4-diOMe
1.4 ˘ 0.10
4.4 ˘ 0.26
>100
17.3 ˘ 0.38
11h
11i
4-Cl
4-F
0.25 ˘ 0.08
0.05 ˘ 0.02
0.03 ˘ 0.02
10.7 ˘ 0.18
1.5 ˘ 0.11
2.6 ˘ 0.07
61.9 ˘ 0.23
23.2 ˘ 0.36
49.1 ˘ 0.25
22.9 ˘ 0.22
1.1 ˘ 0.31
6.6 ˘ 0.25
XL184
a
Prior to the initiation of the kinase reaction with ATP (10
µ
M), compounds and enzyme were incubated
b
for 30 min.
IC50 values obtained with viability assays. Each value is representative of three
independent determinations.

Molecules 2016, 21, 612
6 of 16
Table 3. Enzymatic and cellular results for compound 13a–c.
Enzymatic Inhibition
Proliferative Inhibition (IC50, µM) b
(IC50, µM) a,b
Compound
13a
A
R
c-MET
HeLa
Hep-G2
MCF-7
7.1 ˘ 0.18
>100
>100
71.8 ˘ 0.31
13b
13c
0.02 ˘ 0.09
1.2 ˘ 0.06
4.7 ˘ 0.11
12.8 ˘ 0.28
49.1 ˘ 0.30
1.2 ˘ 0.21
50.1 ˘ 0.25
>100
13d
>10
>100
>100
91.2 ˘ 0.26
13e
13f
>10
>10
66.7 ˘ 0.36
87.8 ˘ 0.13
>100
>100
>100
>100
13g
9.4 ˘ 0.6
>100
>100
27.7 ˘ 0.35
2.8 ˘ 0.23
13h
13i
0.05 ˘ 0.01
4.6 ˘ 0.03
1.7 ˘ 0.04
0.25 ˘ 0.08
0.03 ˘ 0.02
4.2 ˘ 0.31
6.6 ˘ 0.11
43.2 ˘ 0.26
49.1 ˘ 0.13
21.7 ˘ 0.16
2.6 ˘ 0.03
XL184
a
Prior to the initiation of the kinase reaction with ATP (10
µM), compounds and enzyme were incubated
b
for 30 min.
IC50 values obtained with viability assays. Each value is representative of three
independent determinations.
2.2.2. Anti-proliferation against Tumor Cells Assay
All the synthesized compounds were evaluated for their anticancer activity in vitro against
HeLa (human cervical carcinoma), Hep-G2 (human liver cancer) and MCF-7 (human breast cancer).
The results were also summarized in Tables 1–3. It is clear that compound 11c
exhibited good anticancer activity against tested cancer cell lines. Compared to XL184 (IC50 = 6.6
against HeLa), these four compounds all showed better anti-proliferation activity against HeLa with
compound 11c (IC50 = 0.9 M against HeLa) exhibiting the highest activity. Similarly, they also showed
better anti-proliferation activity against Hep-G2 than XL184 (IC50 = 49.1 M), and it is obvious that
M) showed the highest activity, which is far better than XL184. In addition,
M) and 13b (IC50 = 1.2 M) had better results against MCF-7 than XL184
, 11i, 13b, 13h all
µM
µ
µ
compound 13h (IC50 = 1.7
compound 11i (IC50 = 1.1
(IC50 = 2.6 µM).
µ
µ
µ

Molecules 2016, 21, 612
7 of 16
2.2.3. Structure Activity Relationship Analysis
Preliminary structure–activity SAR study appeared that different head groups showed
great differences in cell and enzymatic activity. Among them, quinazolines (compound 9a
11a 13a ), and tetrahydro-pyridothienopyrimidines (compound 9c 11g 13g ) head groups
provided much better activity than pyridines (compound 9b 11d 13d ). For the side chain,
N-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-methoxybenzamide derivatives had lowest activities
while malonamide derivatives had lowest activities. For compound 13a , different R groups provided
,
–
c,
–
c
,
–
i
,
–i
,
–
f,
–f
–i
different activity, when R group was cyclopropane (compound 13b and 13h), the best activity
was observed.
2.2.4. Enzymatic Selectivity Assay
Compound 13b and 13h were further assayed with enzymatic activities against VEGFR-2, c-Kit,
PDGFR-b and EGFR to test their kinase selectivity [31]. The results were summarized in Table 4.
Compound 13b demonstrated extraordinary selectivity against c-Kit (215 fold), PDGFR-b (>500 fold)
and EGFR (>500 fold), but it showed some inhibitory activity against VEGFR-2 (IC50 = 0.1 µM).
Compound 13h exhibited extraordinary selectivity against c-Kit (104 fold), PDGFR-b (144 fold) and
EGFR (>200 fold), and it also showed some inhibitory activity against VEGFR-2 (IC50 = 0.25 µM).
Table 4. Kinase selectivity of compounds 13b and 13h.
Enzyme, IC50, µM a,b
Compound
VEGFR-2
c-Kit
PDGFR-b
EGFR
13b
13h
0.1 ˘ 0.02
4.3 ˘ 0.11
>10
>10
>10
0.25 ˘ 0.02
5.2 ˘ 0.09
7.2 ˘ 0.10
a
Prior to the initiation of the kinase reaction with ATP (10
for 30 min.
µ
M), compounds and enzyme were incubated
b
IC50 values obtained with viability assays. Each value is representative of three
independent determinations.
2.3. Molecular Docking and Molecular Dynamics Simulation Study
In order to better understand the interaction between compounds and kinases, molecular
docking studies on the potent compound 11c and 11i were performed using the Discovery Studio
3.1/CDOCKER protocol [32].
In Figure 2, we showed that compound 11c and 11i could bind to c-MET kinase (PDB: 4MXC)
very well. In addition, they can form hydrophobic interaction in the ATP-binding sites of c-MET and
VEGFR-2. Compounds formed hydrophobic interaction with residues ILE-1084, ALA-1108, LEU-1157,
MET-1160 and ALA-1221 of c-MET.
For the better active compounds 13b and 13h, We demonstrated in Figure 3 the compound 13b and
13h docking into the binding site of c-MET kinase (PDB: 4MXC) and VEGFR-2 kinase (PDB: 4ASE). For
compound 13b, there are two hydrogen bonds formed by residue MET-1160 and ASP-1222, additional,
compound 13b could form hydrophobic interactions with ILE-1084, ALA-1108, MET-1131, LEU-1157,
ALA-1221 to c-MET. Compound 13b can form three hydrogen bonds by residue GLU-885, CYS-919,
and ASP-1046, there also exist hydrophobic interaction with residue LEU-840, VAL-848, ALA-866,
LYS-868, LEU-889, VAL-899, VAL-916, LEU-1035 to VEGFR2. Binding energy of compound 13b is
much better than compound 11c and 11i, the dock interaction energy of compound 13b with c-MET,
compound 11c and 11i with c-MET is
´
70.33 kJ/mol,
´
44.8 kJ/mol and
´
47.6 kJ/mol, respectively.
The nice binding model of compound 13b and 13h with c-MET and VEGFR-2 was consistent with
kinase assay data, which indicates that compounds were potent dual c-MET/VEGFR-2 inhibitors.
To further evaluate the binding affinity between compound 13b and c-MET/VEGFR-2. The
molecular dynamics (MD) simulations were performed by using GROMACS package (version 4.5,

Molecules 2016, 21, 612
8 of 16
University of Groningen, Groningen, The Netherlands), the root-mean-square deviation (RMSD)
fluctuations is a principal criterion to evaluate the stability of the protein-ligand system.
Figure 2. Binding poses of compound 11c (A) and 11i (B) with c-MET. Compound 11c and 11i were
displayed by blue and red, respectively. The important residues and their critical interactions (dash
lines) with compounds in the binding site were depicted, hydrogen bond, hydrophobic interactions
were colored green and carnation, respectively.
Figure 3. Binding poses of compound 13b (A,C) and 13h (B,D) with c-MET and VEGFR2. Compound
13b and 13h were displayed by blue and red, respectively. The important residues and their
critical interactions (dash lines) with compounds in the binding site were depicted, hydrogen bond,
hydrophobic interactions were colored green and carnation, respectively.
As shown in Figure 4, although the RMSD values for compound 13b fluctuated in a narrow
range around 2700 ps, they remained stable for most of the simulation in c-MET complex. RMSD
of compound 13b reach the equilibrium state after about 500 ps and kept stable among the rest of
simulation in VEGFR-2 complex, indicating a stabilities of the dynamics equilibriums. In general, the
maximum RMSD for each case was lower than 0.2 nm, suggesting that c-MET and VEGFR-2 complexes
are reliable and the low RMSD fluctuations of system observed indicated stable binding models of
compound 13b with c-MET and VEGFR-2, respectively.

Molecules 2016, 21, 612
9 of 16
Figure 4. RMSD of compound 13b with c-MET (A) and VEGFR-2 (B), respectively.
3. Experimental Section
3.1. Chemical Synthesis
All reagents were purchased from commercial sources and used without further purification.
1
Melting points are corrected. H-NMR spectra were determined on a Bruker Avance III 400 MHz
spectrometer (Bruker, Billerica, MA, USA) in CDCl3 or DMSO-d6 solution. J values were in Hz.
Chemical shifts were expressed in ppm downfield from internal standard TMS. HRMS data were
obtained using Bruker micro TOF-Q instrument (Bruker) or TOF-MS instrument (Bruker).
3.1.1. General Procedure for the Preparation of 4-Chloro-6,7-dimethoxyquinazoline (Compound 5)
2-amino-dimethyl aminobenzoic acid 2.02 g (10 mmol) and acetic acid formamidine 2.10 g
(20 mmol) were added in 2-methoxy ethanol. The mixture was reflux in 125 ˝C. After evaporation of
solvent, the residue was added in the 10% ammonia solution, stirring, then after filtering, the solid
was washed by water to get the brown solid powder (yield 89%). 1.82 g (8.8 mmol) product was
dissolved in 25 mL SOCl2, and 30 drops of DMF was added. After heating 7 h to reflux, the solvent
was evaporated, then after filtering, the solid was washed by water to get the brown solid powder
4-chloro-6,7-dimethoxyquinazoline (yield 93%).
3.1.2. General Procedure for the Preparation of {tert-Butyl,4-chloro-5,6-dihydropyrido(4’,3’:4,5)thieno
(2,3-d)pyrimidine-7(8H)-carboxylate} (Compound 7)
The N-(tert-Butoxycarbonyl)-4-piperidone, NCCH2CO2Et and Et3N was mixed at room
temperature then stirring for 16 h, and then heated to 120 ˝C for 16 h in DMF with the formamidine
acetate. Then, the intermediate was reacted with POCl3 and DIPEA in toluene to obtain the
compound 7 (yield 89%).
3.1.3. General Procedure for the Preparation of {N-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-3-
((6,7-dimethoxyquinazolin-4-yl)oxy)benzamide} Derivatives Compound 9a–c
Pivaloylacetonitrile 4.07 g (32 mmol) and Phenylhydrazine 3.51 g (32 mmol) were added to
40 mL ethanol and the mixture was heated to reflux for 15 h. After the solvent was evaporated,
[3-(tert-butyl)-1-phenyl-1H-pyrazol-5-amine] was obtained. 138.6 mg (1 mmol) hydroxybenzoic acid in
˝
5 mL THF was added three drops of DMF and reacted with oxalyl chloride 0.5 mL in 0 C. After 1.5 h
reaction, the reaction liquid was dissolved in THF and HCl, which was dissolved in THF solution of
3-(tert-butyl)-1-phenyl-1H-pyrazol-5-amine. After 3 h, the reaction mixture was evaporated; the crude
product was purified by column chromatography to obtain compound
8. Compound 8 was further
reacted with compounds 5, 6, 7 in the presence of K2CO3 to obtain the final products 9a–c.
Compound 9a N-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-((6,7-dimethoxyquinazolin-
:
4-yl)oxy)benzamide. White solid, yield 88%, m.p. 217–219 ˝C. 1H-NMR (400 MHz, DMSO)
δ
10.40

Molecules 2016, 21, 612
10 of 16
(s, 1H), 8.57 (s, 1H), 7.83 (d, J = 7.3 Hz, 1H), 7.79 (s, 1H), 7.64 (t, J = 7.8 Hz, 1H), 7.60 (s, 1H), 7.57
(s, 1H), 7.54 (s, 2H), 7.52 (s, 2H), 7.44 (t, J = 7.8 Hz, 2H), 7.40 (s, 1H), 7.31 (t, J = 7.3 Hz, 1H), 6.40 (s, 1H),
4.01(s, 3H), 3.97(s, 3H), 1.31 (s, 9H). HRMS (m/z): calcd. for 524.2292 ([M + H]+), obsd. 524.2294.
Compound 9b: 4-{3-((3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)carbamoylphenoxy}-N-methylpicolinamide:
1
yellow solid, yield 71%. H-NMR (400 MHz, CDCl3)
δ 8.78 (d, 5.6 Hz, 1H), 8.35–7.95 (m, 2H), 7.94–7.67
(m, 5H), 7.62–7.42 (m, 2H), 7.39–7.05 (m, 2H), 6.74 (s, 1H), 2.85 (s, 3H), 1.29 (s, 9H). 13C-NMR (100 MHz,
CDCl3 ) 169.26, 167.39, 166.32, 158.34, 153.42, 151.87, 148.57, 146.98, 139.89, 135.40, 129.43, 128.96,
δ
128.93, 125.18, 123.62, 118.50, 113.11, 112.47, 95.64, 34.41, 28.32, 26.37.HRMS (m/z): calcd. for 470.2192
([M + H]+), obsd. 470.2181.
Compound 9c
6-dihydropyrido(4’,3’:4,5)thieno(2,3-d)pyrimidine-7(8H)-carboxylate, yellow solid, yield 71%. 1H-NMR
(400 MHz, CDCl3) 8.01–7.67 (m, 5H), 7.67–7.42 (m, 2H), 7.43–7.02 (m, 2H), 4.65–4.55 (m, 2H), 3.70–3.40
(m, 2H), 3.20–3.15 (m, 2H), 1.42 (s, 9H), 1.29 (s, 9H). 13C-NMR (100 MHz, CDCl3)
170.28, 169.27,
:
tert-butyl 4-{3-((3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)carbamoyl)phenoxy}-5,
δ
δ
162.31, 157.47, 154.66, 153.42, 151.87, 148.98, 139.89, 138.69, 129.19, 128.96, 128.93, 126.61, 126.27, 125.18,
122.57, 122.30, 119.22, 117.01, 95.64, 81.20, 43.81, 42.71, 34.41, 28.32, 23.62. HRMS (m/z): calcd. for
625.2597 ([M + H]+), obsd. 625.2611.
3.1.4. General Procedure for the Preparation of 3-Methoxy-N-phenylbenzamide Derivatives
Compound 11a–i
138.6 mg (1 mmol) hydroxybenzoic acid in 5 mL THF was added three drops of DMF and reacted
with oxalyl chloride 0.5 mL in 0 ˝C. After 1.5 h reaction, the reaction liquid was dissolved in THF
and HCl, which was dissolved in THF solution of aniline derivatives. After 3 h, the reaction mixture
was evaporated; the crude product was purified by column chromatography to obtain compounds 10
.
Compounds 10 were further reacted with compounds
final products 11a–i.
5, 6, 7 in the presence of K2CO3 to obtain the
Compound 11a: N-(3,4-dimethoxyphenyl)-3-((6,7-dimethoxyquinazolin-4-yl)oxy)benzamide. Yellow
solid, yield 86%, m.p. 220–222 ˝C. 1H-NMR (400 MHz, CDCl3)
8.62 (s, 1H), 7.90 (s, 1H), 7.81 (d,
δ
J = 7.4 Hz, 2H), 7.60 (t, J = 8.2 Hz, 1H), 7.53 (s, 1H), 7.47 (t, 2H), 7.33 (s, 1H), 6.99 (dd, J = 8.6, 2.3 Hz, 1H),
6.84 (d, J = 8.6 Hz, 1H), 4.07 (d, J = 2.8 Hz, 6H), 3.90 (d, J = 5.2 Hz, 3H), 3.87 (s, 3H). 13C-NMR (100 MHz,
CDCl3)
δ 166.79, 165.05, 154.75, 153.84, 153.57, 149.95, 148.67, 148.21, 138.69, 132.68, 129.19, 126.27,
122.57, 122.29, 118.41, 114.98, 113.43, 111.44, 108.20, 107.06, 56.83.HRMS (m/z): calcd. for 462.1660
([M + H]+), obsd.462.1665. calcd. for 484.11478 ([M + Na]+), obsd.484.1490.
Compound 11b: N-(4-chlorophenyl)-3-((6,7-dimethoxyquinazolin-4-yl)oxy)benzamide. Faint yellow
˝
solid, yield 89%, m.p. 203–205 C. 1H-NMR (400 MHz, DMSO)
δ
10.42 (s, 1H), 8.58 (s, 1H), 7.94 (s, 1H),
7.92 (s, 1H), 7.83 (s, 1H), 7.80 (s, 1H), 7.67 (t, J = 7.8 Hz, 1H), 7.60 (s, 1H), 7.58 (s, 1H), 7.41 (t, 3H), 4.00
(d, J = 5.4 Hz, 6H). 13C-NMR (100 MHz, DMSO)
165.19, 162.11, 155.85, 154.74, 153.57, 147.81, 137.54,
δ
136.45, 130.37, 129.25, 128.67, 127.37, 122.88, 122.46, 121.79, 114.79, 110.88, 107.91, 57.24.HRMS (m/z):
calcd. for 420.1354 ([M + H]+), obsd.436.1059. calcd. for 458. 0878 ([M + Na]+), obsd.458.0883.
Compound 11c: 3-((6,7-di˝methoxyquinazolin-4-yl)oxy)-N-(4-fluorophenyl)benzamide. Yellow solid,
1
yield 86%, m.p. 178–180 C. H-NMR (400 MHz, DMSO)
δ 10.35 (s, 1H), 8.58 (s, 1H), 7.94 (s, 2H),
7.92 (d, J = 2.3 Hz, 2H), 7.79 (q, 1H), 7.67 (t, J = 7.8 Hz, 1H), 7.62–7.56 (m, 2H), 7.42 (s, 1H), 7.20
(t, J = 7.2 Hz, 2H), 4.00 (d, J = 5.2 Hz, 6H). 13C-NMR (100 MHz, DMSO)
δ
167.33, 166.05, 162.07,
159.55, 154.65, 153.84, 153.12, 148.21, 138.69, 134.01, 129.03, 125.77, 122.62, 122.03, 115.11, 111.14,
108.30, 55.43.HRMS (m/z): calcd. for 420.1354 ([M + H]+), obsd.420.1356. calcd. for 442.1174
([M + Na]+), obsd.442.1185.
Compound 11d: 4-{3-((3,4-dimethoxyphenyl)carbamoyl)phenoxy}-N-methylpicolinamide: yellow
solid, yield 82%, 1H-NMR (400 MHz, CDCl3 )
δ
8.78 (d, J = 5.6 Hz, 1H), 8.22–7.89 (m, 2H), 7.67–7.37
(m, 2H), 7.34 (s, 1H), 7.27–7.04 (m, 3H), 6.91 (d, J = 15.4 Hz, 1H), 6.48 (s, 1H), 3.83 (s, 3H), 3.76 (s, 3H),

Molecules 2016, 21, 612
11 of 16
2.85 (s, 3H). 13C-NMR (100 MHz, CDCl3)
δ
168.12, 167.12, 164.25, 157.14, 149.75, 148.47, 147.57, 146.98,
135.32, 132.18, 129.23, 123.62, 118.50, 117.10, 113.43, 113.11, 112.47, 107.06, 56.83, 26.37. HRMS (m/z):
calcd. for 407.1481 ([M + H]+), obsd. 407.1499.
Compound 11e: 4-{3-((4-chlorophenyl)carbamoyl)phenoxy}-N-methylpicolinamide: yellow solid, yield
68%. 1H-NMR (400 MHz, CDCl3)
δ
8.62 (d, J = 5.6 Hz, 1H), 8.01–7.78 (m, 2H), 7.81–7.62 (m, 2H),
7.65–7.42 (m, 2H), 7.48–7.29 (m, 3H), 7.16 (m, 1H), 6.52 (s, 1H), 2.85 (s, 3H). 13C-NMR (100 MHz, CDCl3)
δ
171.77, 169.22, 165.15, 159.14, 149.17, 147.28, 136.46, 135.21, 131.37, 129.44, 127.45, 124.57, 121.78,
118.60, 114.31, 113.17, 24.77. HRMS (m/z): calcd. for 382.0958 ([M + H]+), obsd. 382.0961.
Compound 11f: 4-{3-((4-fluorophenyl)carbamoyl)phenoxy}-N-methylpicolinamide: yellow solid, yield
82%, 1H-NMR (400 MHz, CDCl3 ) δ 8.74 (d, J = 5.6 Hz, 1H), 8.02–7.76 (m, 2H), 7.72–7.46 (m, 4H), 7.34
(m, 1H), 7.21–7.01 (m, 3H), 6.50 (s, 1H), 2.85 (s, 3H). 13C-NMR (100 MHz, CDCl3)
δ 169.39, 168.32,
167.05, 163.07, 159.55, 158.34, 148.57, 146.98, 135.40, 134.03, 132.01, 128.43, 123.62, 122.66, 121.58, 118.51,
115.10, 113.90, 112.17, 110.47, 28.37. HRMS (m/z): calcd. for 407.1481 ([M + H]+), obsd. 407.1499.
Compound 11g
(4’,3’:4,5)thieno(2,3-d)pyrimidine-7(8H)-carboxylate: yellow solid, yield 71%, m.p. 103–105 ˝C.
1H-NMR (400 MHz, CDCl3 )
8.92 (s, 1H), 8.50 (s, 1H), 7.65–7.40 (m, 2H), 7.34 (m, 1H), 7.29–7.07
(m, 3H), 6.91 (m, 1H), 4.70 (s, 2H), 3.81 (s, 3H), 3.78 (s, 3H), 3.59–3.43 (m, 2H), 3.17 (m, 2H), 1.42
(s, 9H). 13C-NMR (100 MHz, CDCl3)
170.28, 166.05, 162.31, 157.47, 154.66, 149.95, 148.98, 148.67,
:
tert-butyl 4-{3-((3,4-dimethoxyphenyl)carbamoyl)phenoxy}-5,6-dihydropyrido
δ
δ
138.69, 132.68, 129.19, 126.61, 126.27, 122.57, 122.30, 119.22, 118.40, 117.01, 113.43, 107.06, 81.20, 56.83,
43.81, 42.71, 28.33, 23.62. HRMS (m/z): calcd. for 563.1964 ([M + H]+), obsd. 563.1921.
Compound 11h: tert-butyl 4-{3-((4-chlorophenyl)carbamoyl)phenoxy}-5,6-dihydropyrido(4’,3’:4,5)
thieno(2,3-d)pyrimidine-7(8H)-carboxylate: yellow solid, yield 74%, 1H-NMR (400 MHz, CDCl3)
δ
8.50
(s, 1H), 7.81–7.67 (m, 2H), 7.61–7.42 (m, 2H), 7.42–7.16 (m, 4H), 4.65 (s, 2H), 3.67–3.40 (m, 2H), 3.17
(m, 2H), 1.42 (s, 9H). 13C-NMR (100 MHz, CDCl3 )
173.11, 168.12, 164.45, 159.26, 155.78, 149.12, 139.57,
δ
136.46, 130.37, 129.26, 128.01, 127.74, 126.77, 123.78, 122.86, 121.41, 118.12, 116.21, 79.31, 44.25, 43.78,
27.32, 24.42. HRMS (m/z): calcd. for 537.1363 ([M + H]+), obsd. 537.1378.
Compound 11i: tert-butyl 4-{3-((4-fluorophenyl)carbamoyl)phenoxy}-5,6-dihydropyrido(4’,3’:4,5)
1
thieno(2,3-d)pyrimidine-7(8H)-carboxylate: yellow solid, yield 77%, H-NMR (400 MHz, CDCl3)
δ
8.50 (s, 1H), 7.73–7.43 (m, 4H), 7.34–7.15 (m, 4H), 4.65 (s, 2H), 3.65–3.42 (m, 2H), 3.18 (m, 2H), 1.42
(s, 9H). 13C-NMR (100 MHz, CDCl3 )
δ
171.01, 167.25, 163.42, 162.01, 159.45, 158.27, 155.84, 147.88,
137.32, 135.05, 134.00, 130.12, 127.42, 125.77, 123.66, 122.57, 121.70, 119.62, 118.71, 116.10, 114.93, 82.18,
44.28, 43.54, 27.43, 24.55. HRMS (m/z): calcd. for 521.1659 ([M + H]+), obsd. 521.1711.
3.1.5. General Procedure for the Preparation of
N1-(3-Fluoro-4-hydroxyphenyl)-N3-(4-fluorophenyl)malonamide Derivatives Compounds 12
Diethyl malonate 2.53 mL (17 mmol), iodomethane or 1,2-dibromoethane or 1,3-dibromoethane
(22 mmol), K2CO3 5.7 g (42 mmol) and tetrabutylammonium bromide 0.27 g (0.08 mmol) were added
in DMF. The mixture is stirred for 16 h at room temperature. After evaporation of solvent, the residue
was extracted with ethyl acetate 100 mL three times, and the organic layer was washed with water.
After the concentration of the solvent, colorless oil diethyl cyclopropane-1,1-dicarboxylatederivatives
were obtained (yield 89%).
Diethyl cyclopropane-1,1-dicarboxylatederivatives (1.0 eq.) were dissolved in EtOH. KOH (1.0 eq.)
in ethanol solution was added and stirred for 5 h. After the completion of the reaction, the intermediate
˝
was dissolved in THF solution at
´
15 C. 4-Methylmorpholine (1.2 eq.), isobutyl chloroformate
(1.0 eq.) and 4-amino-2-fluorophenol (1.0 eq.) were added. The crude product was purified by column
chromatography, and the above process was repeated. The final product compounds 12 were obtained.

Molecules 2016, 21, 612
12 of 16
3.1.6. General Procedure for the Preparation of
N1-(3-Fluoro-4-methoxyphenyl)-N3-(4-fluorophenyl)malonamide Derivatives Compound 13a–i
Compounds 12 were further reacted with compounds
the final products 13a–i as mentioned above.
5, 6, 7 in the presence of K2CO3 to obtain
Compound 13a: N1-{4-((6,7-dimethoxyquinazolin-4-yl)oxy)-3-fluorophenyl}-N3-(4-fluorophenyl)-2,
2-dimethylmalonamide. White solid, yield 85%, m.p. 210–212 ˝C. 1H-NMR (400 MHz, CDCl3)
8.84
(s, 1H), 8.51 (s, 1H), 8.22 (s, 1H), 7.70 (m, 1H), 7.48 (s, 1H), 7.44–7.23 (m, 2H), 7.23–7.15 (m, 1H), 6.97
(t, J = 8.6 Hz, 1H), 3.99 (d, J = 4.3 Hz, 1H), 1.62 (s, 1H). 13C-NMR (100 MHz, CDCl3)
172.19, 171.92,
δ
δ
165.66, 162.17, 159.64, 156.11, 155.44, 153.27, 152.81, 150.33, 149.47, 136.40, 136.30, 136.20, 136.07, 133.02,
124.10, 122.59, 115.91, 110.17, 109.39, 109.15, 106.81, 100.93, 56.36, 50.76, 24.18. HRMS (m/z): calcd. for
523.1788 ([M + H]+), obsd.535.1791.
Compound 13b
cyclopropane-1,1-dicarboxamide. Yellow solid, yield 86%, m.p. 180–182 C. H-NMR (400 MHz,
CDCl3) 9.66 (s, 1H), 8.52 (s, 1H), 8.47 (s, 1H), 7.67 (d, J = 11.1 Hz, 1H), 7.48 (s, 1H), 7.38 (dd, J = 9.0, 4.8
Hz, 1H), 7.20 (d, J = 5.5 Hz, 1H), 6.98 (t, J = 8.6 Hz, 1H), 3.99 (d, J = 4.5 Hz, 3H), 1.66 (t, J = 6.1 Hz, 1H),
1.58–1.51 (m, 1H). 13C-NMR (100 MHz, CDCl3)
169.43, 168.43, 164.68, 156.04, 152.69, 150.36, 149.45,
:
N-{4-[(6,7-dimethoxyquinazolin-4-yl)oxy]-3-fluorophenyl}-N-(4-fluorophenyl)
˝
1
δ
δ
136.42, 136.03, 124.07, 122.95, 122.87, 116.10, 115.96, 115.73, 110.20, 109.63, 109.40, 106.78, 100.96, 56.37,
31.93, 29.70, 29.29, 22.69, 17.61, 14.12. HRMS (m/z): calcd. for 521.1631 ([M + H]+), obsd.521.1634.
Compound 13c
:
N-{4-((6,7-dimethoxyquinazolin-4-yl)oxy)-3-flu˝orophenyl}-N-(4-fluorophenyl)
cyclobutane-1,1-dicarboxamide. White solid, yield 80%, m.p. 250–252 C. 1H-NMR (400 MHz, CDCl3)
δ
8.58 (s, 1H), 8.53 (d, J = 7.2 Hz, 1H), 8.16 (d, J = 7.5 Hz, 1H), 7.80 (dd, J = 11.9, 2.1 Hz, 1H), 7.57–7.48
(m, 1H), 7.35–7.30 (m, 1H), 7.28 (d, J = 3.4 Hz, 1H), 7.03 (t, J = 8.5 Hz, 1H), 4.06 (d, J = 4.5 Hz, 1H),
2.06–1.90 (m, 1H), 1.28–1.23 (m, 1H). 13C-NMR (101 MHz, CDCl3)
170.54, 170.40, 164.67, 160.91,
δ
158.47, 156.02, 155.52, 153.05, 152.69, 150.34, 149.44, 136.64, 136.12, 133.38, 124.14, 122.02, 121.94, 115.88,
115.65, 110.16, 109.09, 108.86, 106.78, 100.93, 56.36, 56.02, 29.76, 15.67. HRMS (m/z): calcd. for 535.1788
([M + H]+), obsd.535.1793.
Compound 13d: N1-(4-fluorophenyl)-2,2-dimethyl-N3-{4-((2-(methylcarbamoyl)pyridin-4-yl)oxy]
phenyl}malonamide. Faint yellow solid, yield 82%, m.p. 113–115 ˝C. 1H-NMR (400 MHz, CDCl3)
δ
8.72 (s, 1H), 8.54 (s, 1H), 8.37 (d, J = 5.6 Hz, 1H), 8.02 (d, J = 4.0 Hz, 1H), 7.66 (d, J = 1.9 Hz, 1H), 7.60–7.50
(m, 3H), 7.09–6.99 (m, 4H), 6.94 (dd, J = 5.6, 2.5 Hz, 1H), 2.99 (d, J = 5.1 Hz, 3H), 1.70 (s, 6H). 13C-NMR
(100 MHz, CDCl3)
δ 171.71, 166.36, 164.46, 160.93, 158.50, 152.26, 150.23, 149.67, 135.10, 133.32, 122.47,
122.39, 122.32, 121.43, 115.81, 115.59, 114.10, 110.12, 50.69, 29.70, 26.15, 25.36, 24.24. HRMS (m/z): calcd.
for 451.1776 ([M + H]+), obsd.451.1779. Calcd. for 473.1596 ([M + Na]+), obsd.473.1602.
Compound 13e: N-(4-fluorophenyl)-N-{4-((2-(methylcarbamoyl)pyridin-4-yl)oxy)phenyl}cyclopropane-1,
˝
1-dicarboxamide. White solid, yield 82%, m.p. 138–140 C. 1H-NMR (400 MHz, CDCl3)
δ 9.46 (s, 2H),
8.31 (d, J = 5.6 Hz, 1H), 7.99 (d, J = 4.9 Hz, 1H), 7.54–7.50 (m, 2H), 7.49 (s, 1H), 7.43–7.36 (m, 1H), 6.99
(s, 1H), 6.96 (d, J = 2.6 Hz, 1H), 6.94 (s, 1H), 6.91 (4, 1H), 4.03 (q, 1H), 2.88 (d, J = 5.1 Hz, 3H), 1.19
(t, 2H), 1.13 (d, J = 6.1 Hz, 2H). 13C-NMR (100 MHz, CDCl3)
δ 169.65, 169.34, 166.39, 164.64, 152.09,
150.24, 149.81, 135.18, 133.43, 123.21, 122.91, 121.42, 115.72, 115.50, 114.39, 109.72, 64.43, 60.43, 28.89,
26.18, 25.35, 21.05, 17.91, 14.19. HRMS (m/z): calcd. for 624.2087 ([M + H]+), obsd.449.1620. calcd. for
471.1439 ([M + Na]+), obsd.471.1464.
Compound 13f: N-(4-fluorophenyl)-N-{4-((2-(methylcarbamoyl)pyridin-4-yl)oxy)phenyl}cyclobutane-1,
˝
1-dicarboxamide. White solid, yield 77%, m.p. 192–194 C. 1H-NMR (400 MHz, CDCl3)
δ 8.29 (s, 1H),
8.27 (d, J = 5.1 Hz, 1H), 8.14 (s, 1H), 7.94 (d, J = 4.5 Hz, 1H), 7.60–7.56 (m, 1H), 7.54 (s, 1H), 7.49–7.38
(m, 1H), 6.96 (dd, J = 8.6, 4.5 Hz, 1H), 6.92 (s, 1H), 6.86 (dd, J = 5.5, 2.5 Hz, 1H), 2.92 (d, J = 5.1 Hz,
1H), 2.68 (t, J = 7.9 Hz, 1H), 2.01–1.88 (m, 1H). 13C-NMR (100 MHz, CDCl3)
δ
170.49, 170.45, 166.31,
164.53, 152.28, 150.10, 149.71, 135.33, 121.96, 121.88, 121.81, 121.43, 115.80, 115.57, 114.09, 110.09, 64.42,

Molecules 2016, 21, 612
13 of 16
55.91, 29.78, 26.14, 25.35, 15.68. HRMS (m/z): calcd. for 463.1776 ([M + H]+), obsd.463.1779. calcd. for
485.1596 ([M + Na]+), obsd.485.1602.
Compound 13g: tert-butyl-4-{2-fluoro-4-(3-((4-fluorophenyl)amino)-2,2-dimethyl-3-oxopropanamido)
phenoxy}-5,6-dihydropyrido(4’,3’:4,5)thieno(2,3-d)pyrimidine-7(8H)-carboxylate. Faint yellow solid,
yield 75%, m.p. 126–128 ˝C. 1H-NMR (400 MHz, CDCl3)
δ
8.92 (s, 1H), 8.48 (s, 1H), 8.24 (s, 1H), 7.75
(dd, 1H), 7.53–7.45 (m, 2H), 7.25–7.18 (m, 2H), 7.05 (t, J = 8.6 Hz, 2H), 4.74 (s, 2H), 3.80 (t, J = 5.4 Hz,
2H), 3.18 (s, 2H), 1.69 (s, 6H), 1.51 (s, 9H). 13C-NMR (100 MHz, CDCl3)
171.94, 171.13, 169.06, 162.68,
δ
159.13, 158.67, 154.55, 152.49, 136.38, 135.74, 135.61, 132.99, 124.02, 122.59, 122.51, 118.09, 115.93, 115.81,
115.71, 109.35, 109.11, 80.57, 50.74, 31.93, 29.70, 29.66, 29.37, 28.43, 24.20, 22.70, 19.55, 14.12. HRMS
(m/z): calcd. for 624.2087 ([M + H]+), obsd.624.2091. Calcd. for 646.1906 ([M + Na]+), obsd.646.1913.
Compound 13h: tert-butyl-4-{2-fluoro-4-(1-((4-fluorophenyl)carbamoyl)cyclopropanecarboxamido)
phenoxy}-5,6-dihydropyrido(4’,3’:4,5)thieno(2,3-d)pyrimidine-7(8H)-carboxylate. White solid, yield
82%, m.p. 171–173 ˝C. 1H-NMR (400 MHz, CDCl3)
δ
9.76 (s, 1H), 8.52 (s, 1H), 8.41 (s, 1H), 7.65–7.34
(m, 3H), 7.22–7.12 (m, 2H), 6.97 (t, J = 8.6 Hz, 2H), 4.66 (s, 2H), 3.72 (t, J = 5.6 Hz, 2H), 3.11 (s, 2H),
1.54 (dd, J = 7.7, 4.9 Hz, 2H), 1.43 (s, 9H), 1.18 (t, J = 7.1 Hz, 4H). 13C-NMR (100 MHz, CDCl3)
δ
169.56, 169.03, 168.49, 162.68, 161.13, 158.69, 155.43, 154.58, 152.97, 152.49, 136.55, 136.45, 135.69, 135.56,
132.87, 123.95, 123.02, 118.21, 116.19, 115.93, 115.81, 109.70, 109.47, 80.70, 60.54, 29.80, 29.34, 28.53,
21.16, 17.65, 14.25. HRMS (m/z): calcd. for 622.1930 ([M+H]+), obsd.622.1930. Calcd. for 644.1750
([M + Na]+), obsd.644.1793.
Compound 13i
: tert-butyl-4-{2-fluoro-4-(1-((4-fluorophenyl)carbamoyl)cyclobutanecarboxamido)
phenoxy}-5,6-dihydr˝opyrido(4’,3’:4,5)thieno(2,3-d)pyrimidine-7(8H)-carboxylate. Yellow solid, yield
1
83%, m.p. 101–103 C. H-NMR (400 MHz, CDCl3)
δ 8.48 (s, 1H), 8.36 (s, 1H), 7.96 (s, 1H), 7.78
(dd, J = 11.9, 2.1 Hz, 1H), 7.56–7.41 (m, 2H), 7.27–7.18 (m, 2H), 7.04 (t, J = 8.6 Hz, 2H), 4.74 (s, 2H), 3.80
(t, J = 5.4 Hz, 2H), 3.18 (s, 2H), 2.85–2.65 (m, 4H), 2.05–1.99 (m, 2H), 1.51 (s, 9H). 13C-NMR (100 MHz,
CDCl3)
δ 170.48, 170.16, 169.07, 162.68, 160.91, 158.51, 155.46, 154.54, 152.99, 152.47, 136.60, 135.79,
135.55, 134.32, 133.24, 131.70, 124.05, 121.99, 121.91, 118.09, 115.91, 115.68, 115.47, 109.04, 108.81, 80.56,
61.84, 55.94, 31.93, 29.75, 29.70, 28.43, 15.68. HRMS (m/z): calcd. for 636.2087 ([M + H]+), obsd.636.2068.
Calcd. for 658.1906 ([M + Na]+), obsd.658.1912.
3.2. Cell Proliferative Assay
The anti-proliferative activities of synthesized compounds against HeLa, Hep-G2 and MCF-7
cells were evaluated by MTT assay [10]. HeLa cells were grown to log phase in RPMI 1640 medium
supplemented with 10% fetal bovine serum. Hep-G2 and MCF-7 cells were grown to log p´h1ase in
DMEM medium supplemented with 10% fetal bovine serum. After diluting to 5
ˆ
105 cells
¨
L
with
the complete medium, 100 µL of the obtained cell suspension was added to each well of 96-well culture
plates. The subsequent incubation was permitted at 37 ˝C, 5% CO2 atmosphere for 48 h before the
anti-proliferative assessments. Tested samples at pre-set concentrations were added to 6 wells. Before
the anti-proliferative assessments, 20
µ
L of PBS containing 2.5 mg
¨
mL´1 of MTT was added to each
well. Four h later, 100 L extraction solution (DMSO) was added to each well and the optical density
µ
was measured at a wavelength of 570 nm on an ELISA microplate reader.
3.3. In Vitro Kinase Assay
In vitro kinase inhibitory ability was determined using HTScan MET Kinase Assay Kit, HTScan
VEGF Receptor 2 Kinase Assay Kit, HTScan c-Kit Kinase Assay Kit, HTScan PDGF Receptor
β
Kinase Assay Kit and HTScan EGFR Kinase Assay Kit(purchased from Cell Signaling Technology, Inc.
Danvers, MA, USA) by colorimetric ELISA assay according to the manufacturer’s instructions. Briefly,
reaction cocktail containing recombinant human MET kinase or other kinases were incubated with
various concentrations of tested compounds or DMSO (0.1%) for 5 min at room temperature, and then
ATP/substrate peptide cocktail was added to the pre-incubated reaction cocktail. After incubation at

Molecules 2016, 21, 612
14 of 16
room temperature for 30 min, the reaction was stopped and transferred to a 96-wellstreptavidin-coated
plate, and incubated for 1 h at room temperature. Primary antibody (phosphorylated tyrosine
monoclonal antibody (pTyr-100), 1:1000 in PBS/T with 1% bovine serum albumin (BSA)) was added
into per well until the wells were washed thrice with PBS/T. After incubated at room temperature
for 1 h, phosphorylation of the substrate was monitored with HRP-labeled anti-mouse IgG antibody
(1:500 in PBS/T with 1% BSA), followed by a chromogenic reaction. Finally, the kinase assay was
detected at 450 nm with microplate reader. The reaction processed with only DMSO (0.1%) served as a
vehicle control. The results were expressed as percent kinase activity of the vehicle control, and IC50
was defined as the compound concentration that resulted in 50% inhibition of enzyme activity. The
kinase assay was performed thrice independently.
3.4. Molecular Dockingand Dynamics Simulation
Molecular docking of compounds into the three dimensional X-ray structure of c-MET (PDB code:
4MXC) and VEGFR-2 (PDB code: 4ASE) was carried out using the Discovery Studio (version3.1) as
implemented through the graphical user interface Discovery Studio CDOCKER protocol [32].
The three-dimensional structure of all compounds was constructed using ChemBio 3D Ultra
11.0 software (Chemical Structure Drawing Standard; Cambridge Soft corporation, Waltham, MA,
USA), then it was energetically minimized by using MMFF94 with 5000iterations and minimum RMS
gradient of 0.10. The crystal structures of VEGFR-2 kinase were retrieved from the RCSB Protein Data
Bank (http://www.rcsb.org/pdb/home). All bound waters and ligands were eliminated from the
protein and the polar hydrogen was added. The whole protein structure was defined as are acceptor
and the site sphere was selected based on ATP binding site of 4ASE or 4MXC. Compounds were placed
during the molecular docking procedure. Types of interactions of the docked protein with ligand were
analyzed after the end of molecular docking.
To further confirm the binding model of compound 13b with c-MET and VEGFR-2, respectively,
MD simulations was performed using the GROMACS package (version 4.5, University of
Groningen) [33]. By using the AMBER99 force field and general AMBER force field (gaff), receptor
and ligands were charged, respectively [34]. The simulations study were carried out under periodic
boundary conditions (PBC) with minimum distance (0.1 nm) between the kinase and the edge of the
box. The complex of compound 13b with protein were solvated in a cubic box of TIP3P water molecules
and neutralized by adding Na+ and Cl´ to mimic physiological NaCl concentration of 0.15 M. Prior
to MD simulations, energy minimization were performed to remove bad contacts, 100-ps NVT and
100-ps NPT ensembles with protein and ligand position restraints were carried out to equilibrate each
system. Finally, 3-ns MD production simulations were carried out for each system with a 2-fs time step
at constant pressure (1 atm) and temperature (300 K).
4. Conclusions
In this study, a series of 3-methoxy-N-phenylbenzamide derivatives, N-(3-(tert-butyl)-1-phenyl-
1H-pyrazol-5-yl) benzamide derivatives and N1-(3-fluoro-4-methoxyphenyl)-N3-(4-fluorophenyl)
malonamide derivatives were synthesized, and some of them were identified as potent and selective
c-MET inhibitors. Compound 13b showed the most potent inhibitory activity against c-MET with
IC50 of 0.02
compound 11c
activity in vitro. Importantly, compound 13h showed the highest anti-proliferation activity against
Hep-G2 with IC50 of 1.7 M, which is better than the c-MET inhibitor XL184, suggesting that compound
µM, and it exhibited good anticancer activity against tested cancer cell lines. In addition,
,
11i 13h also demonstrated potent c-MET inhibitory activity and excellent anticancer
,
µ
13h may have great potential for liver cancer therapy. Kinase selectivity assay suggested that compound
13b and 13h also showed a little inhibitory activity against VEGFR-2. Moreover, molecular docking
results disclosed binding modes of these potent inhibitors and c-MET. Therefore, compound 11c
13b, 13h are potent c-MET inhibitors and could be potential anticancer agents.
, 11i,

Molecules 2016, 21, 612
15 of 16
Acknowledgments: We are grateful to TANG Bioscience (Shanghai, China) for their help in kinase assay.
This work is supported by grants from Key Projects of the National Science and Technology Pillar Program
(2012BAI30B02), National Natural Science Foundation (Nos. 81260628, 81303270, and U1303124) and Liaoning
Science and Technology Project (2013226027-4).
Author Contributions: J.-H.W. and L.-X.C. conceived and designed the experiments; Y.-N.J., K.Z.,
S.-Y.G. and G.-H.W. performed the experiments; Y.-N.J. and K.Z. analyzed the data; J.H. contributed
reagents/materials/analysis tools; J.-H.W. wrote the paper.
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
2.
3.
4.
5.
6.
7.
Liao, J.J. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase
inhibitors. J. Med. Chem. 2007, 50, 409–424. [CrossRef] [PubMed]
Wilhelm, S.; Chien, D.S. BAY 43-9006: Preclinical data. Curr. Pharm. Des. 2002, 8, 2255–2257. [CrossRef]
[PubMed]
Jennifer, S.; Lazarus, R.A.; Xiaoyi, Y. Crystal structure of the HGF β-chain in complex with the Sema domain
of the MET receptor. Embo J. 2004, 23, 2325–2335.
Bottaro, D.P.; Rubin, J.S.; Faletto, D.L. Identification of the hepatocyte growth factor receptor as the c-MET
protooncogene product. Science 1991, 251, 802–804. [CrossRef] [PubMed]
Naldini, L.; Weidner, K.M.; Vigna, E. Scatter factor and hepatocyte growth factor are indistinguishable
ligands for the MET receptor. Int. J. Miner. Metal. Mater. 1991, 10, 2867–2878.
Huh, C.G.; Factor, V.M.; Sánchez, A. Hepatocyte growth factor/c-MET signaling pathway is required for
efficient liver regeneration and repair. Proc. Natl. Acad. Sci. USA 2004, 101, 4477–4482. [CrossRef] [PubMed]
Brinkmann, V.; Foroutan, H.; Sachs, M. Hepatocyte growth factor/scatter factor induces a variety of
tissue-specific morphogenic programs in epithelial cells. J. Cell Biol. 1995, 131, 1573–1586. [CrossRef]
[PubMed]
8.
9.
Comoglio, P.M.; Giordano, S.; Trusolino, L. Drug development of MET inhibitors: Targeting oncogene
addiction and expedience. Nat. Rev. Drug Discov. 2008, 7, 504–516. [CrossRef] [PubMed]
Trusolino, L.; Comoglio, P.M. Scatter-factor and semaphorin receptors: Cell signalling for invasive growth.
Nat. Rev. Cancer 2002, 2, 289–300. [CrossRef] [PubMed]
10. Xu, Y.Y.; Li, S.N.; Yu, G.J. Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of
epidermal growth factor receptor with antitumor activity. Bioorg. Med. Chem. 2013, 21, 6084–6091. [CrossRef]
[PubMed]
11. Seiwert, T.Y.; Jagadeeswaran, R.; Faoro, L. The MET receptor tyrosine kinase is a potential novel therapeutic
target for head and neck squamous cell carcinoma. Cancer Res. 2009, 69, 3021–3031. [CrossRef] [PubMed]
12. Okuda, K.; Sasaki, H.; Yukiue, H.; Yano, M.; Fujii, Y. MET gene copy number predicts the prognosis for
completely resected non-small cell lung cancer. Cancer Sci. 2008, 99, 2280–2285. [CrossRef] [PubMed]
13. Liu, X.; Newton, R.C.; Scherle, P.A. Development of c-MET pathway inhibitors. Expert Opin. Investig. Drugs
2011, 20, 1225–1241. [CrossRef] [PubMed]
14. Matsumoto, S.; Miyamoto, N.; Hirayama, T. Structure-based design, synthesis, and evaluation of
imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-MET and VEGFR2 kinase
inhibitors. Bioorg. Med. Chem. 2013, 21, 7686–7698. [CrossRef] [PubMed]
15. Saavedra, O.; Szhan, C. N3-arylmalonamides: A new series of thieno[3,2-b]pyridine based inhibitors of
c-MET and VEGFR2 tyrosine kinases. Bioorg. Med. Chem. Lett. 2009, 19, 6836–6839. [CrossRef] [PubMed]
16. Tang, Q.; Zhang, G.; Du, X. Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing
5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-MET kinase inhibitors. Bioorg. Med. Chem. 2014, 22,
1236–1249. [CrossRef] [PubMed]
17. Mifune, Y.; Matsumoto, T.; Takayama, K. The effect of platelet-rich plasma on the regenerative therapy of
muscle derived stem cells for articular cartilage repair. Osteoarthr. Cartil. 2013, 21, 175–185. [CrossRef]
[PubMed]
18. Simard, J.R.; Getlik, M.; Grütter, C. Fluorophore labeling of the glycine-rich loop as a method of identifying
inhibitors that bind to active and inactive kinase conformations. J. Am. Chem. Soc. 2010, 132, 4152–4160.
[CrossRef] [PubMed]

Molecules 2016, 21, 612
16 of 16
19. Hamed, M.M. Quinazoline and tetrahydropyridothieno[2,3-d]pyrimidine derivatives as irreversible EGFR
tyrosine kinase inhibitors: Influence of the position 4 substituent. Med. Chem. Commun. 2013, 4, 1202–1207.
[CrossRef]
20. Liu, L.; Norman, M.H.; Lee, M. Structure-based design of novel class II c-MET inhibitors: 2. SAR and kinase
selectivity profiles of the pyrazolone series. J. Med. Chem. 2012, 55, 1868–1897. [CrossRef] [PubMed]
21. Dussault, I.; Bellon, S.F. From concept to reality: The long road to c-MET and RON receptor tyrosine kinase
inhibitors for the treatment of cancer. Anti-Cancer Agents Med. Chem. 2009, 9, 221–229. [CrossRef]
22. Bowles, D.W.; Kessler, E.R.; Jimeno, A. Multi-targeted tyrosine kinase inhibitors in clinical development:
focus on XL-184 (cabozantinib). Drugs of Today 2011, 47, 857–868. [CrossRef] [PubMed]
23. She, N.; Zhuo, L.; Jiang, W. Design, synthesis and evaluation of highly selective pyridone-based class II MET
inhibitors. Bioorg. Med. Chem. Lett. 2014, 24, 3351–3355. [CrossRef] [PubMed]
24. Shi, L.; Wu, T.T.; Wang, Z. Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual
inhibitors of c-MET and VEGFR-2. Bioorg. Med. Chem. 2014, 22, 4735–4744. [CrossRef] [PubMed]
25. Lee, J.S.; Kang, Y.; Kim, J.T. The anti-angiogenic and anti-tumor activity of synthetic phenylpropenone
derivatives is mediated through the inhibition of receptor tyrosine kinases. Eur. J. Pharmaco. 2012, 677, 22–30.
[CrossRef] [PubMed]
26. Sadek, M.M.; Serrya, R.A.; Kafafy, A.H. Discovery of new HER2/EGFR dual kinase inhibitors based on the
anilinoquinazoline scaffold as potential anti-cancer agents. J. Enzyme Inhib. Med. Chem. 2014, 29, 215–222.
[CrossRef] [PubMed]
27. Wu, C.H.; Coumar, M.S.; Chu, C.Y. Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold
based epidermal growth factor receptor (EGFR) kinase inhibitors: The role of side chain chirality and michael
acceptor group for maximal potency. J. Med. Chem. 2010, 53, 7316–7326. [CrossRef] [PubMed]
28. Nourry, A.; Zambon, A.; Davies, L. BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a
meta substituted middle ring. J. Med. Chem. 2010, 53, 1964–1978. [CrossRef] [PubMed]
29. Chackalamannil, S.; Chung, S.; Stamford, A.W. Highly potent and selective inhibitors of endothelin
converting enzyme. Bioorg. Med. Chem. Lett. 1996, 6, 1257–1260. [CrossRef]
30. Liu, Z.; Ai, J.; Peng, X. Novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent
c-MET/ALK multikinase inhibitory activities. ACS Med. Chem. Lett. 2014, 5, 304–308. [CrossRef] [PubMed]
31. Chen, H.M.; Tsai, C.H.; Hung, W.C. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growh of
pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling. Oncotarget 2015, 6, 14940–14952.
[CrossRef] [PubMed]
32. Discovery Studio Modeling Environment; Version 3.5; Accelrys Software Inc.: San Diego, CA, USA, 2011.
33. Pronk, S.; Páll, S.; Schulz, R.; Larsson, P.; Bjelkmar, P.; Apostolov, R.; Shirts, M.R.; Smith, J.C.; Kasson, P.M.;
van der Spoel, D.; et al. GROMACS 4.5: A high-throughput and highly parallel open source simulation
toolkit. Bioinformatics 2013, 29, 845–854. [CrossRef] [PubMed]
34. Wang, J.; Wolf, R.M.; Caldwell, J.W.; Kollman, P.A.; Case, D.A. Development and testing of a general amber
force field. J. Comput. Chem. 2004, 25, 1157–1174. [CrossRef] [PubMed]
Sample Availability: Samples of the compounds are not available from the authors.
©
2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).